Cargando…
Disease-modifying therapies alter gut microbial composition in MS
OBJECTIVE: To determine the effects of the disease-modifying therapies, glatiramer acetate (GA) and dimethyl fumarate (DMF), on the gut microbiota in patients with MS. METHODS: Participants with relapsing MS who were either treatment-naive or treated with GA or DMF were recruited. Peripheral blood m...
Autores principales: | Katz Sand, Ilana, Zhu, Yunjiao, Ntranos, Achilles, Clemente, Jose C., Cekanaviciute, Egle, Brandstadter, Rachel, Crabtree-Hartman, Elizabeth, Singh, Sneha, Bencosme, Yadira, Debelius, Justine, Knight, Rob, Cree, Bruce A.C., Baranzini, Sergio E., Casaccia, Patrizia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278850/ https://www.ncbi.nlm.nih.gov/pubmed/30568995 http://dx.doi.org/10.1212/NXI.0000000000000517 |
Ejemplares similares
-
Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models
por: Cekanaviciute, Egle, et al.
Publicado: (2017) -
Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria
por: Cekanaviciute, Egle, et al.
Publicado: (2018) -
The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017) -
Body Mass Index in Multiple Sclerosis modulates ceramide-induced DNA methylation and disease course
por: Castro, Kamilah, et al.
Publicado: (2019) -
Immune cell-specific transcriptional profiling highlights distinct molecular pathways controlled by Tob1 upon experimental autoimmune encephalomyelitis
por: Didonna, Alessandro, et al.
Publicado: (2016)